Investor relations

Helix BioPharma’s product development initiatives include its novel L-DOS47 new drug product candidate for the treatment of inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer and CAR-T therapies.

For more information, contact Investor Relations or Shareholder Services.

TSX: HBPFrankfurt: HBP